CN1220515C - Medicine for treating throat disease - Google Patents
Medicine for treating throat disease Download PDFInfo
- Publication number
- CN1220515C CN1220515C CN 200410010708 CN200410010708A CN1220515C CN 1220515 C CN1220515 C CN 1220515C CN 200410010708 CN200410010708 CN 200410010708 CN 200410010708 A CN200410010708 A CN 200410010708A CN 1220515 C CN1220515 C CN 1220515C
- Authority
- CN
- China
- Prior art keywords
- medicine
- effect
- throat
- present
- fructus momordicae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 47
- 201000010099 disease Diseases 0.000 title claims abstract description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 24
- 229940079593 drug Drugs 0.000 title description 19
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 241000628997 Flos Species 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 35
- 210000003800 pharynx Anatomy 0.000 abstract description 20
- 201000007100 Pharyngitis Diseases 0.000 abstract description 19
- 238000002474 experimental method Methods 0.000 abstract description 9
- 210000004072 lung Anatomy 0.000 abstract description 8
- 206010011224 Cough Diseases 0.000 abstract description 6
- 230000036407 pain Effects 0.000 abstract description 6
- 230000001717 pathogenic effect Effects 0.000 abstract description 6
- 241000894006 Bacteria Species 0.000 abstract description 5
- 230000012010 growth Effects 0.000 abstract description 5
- 208000037976 chronic inflammation Diseases 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 235000013399 edible fruits Nutrition 0.000 abstract description 3
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 208000017574 dry cough Diseases 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 231100000419 toxicity Toxicity 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract description 2
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 235000017965 Asarum canadense Nutrition 0.000 abstract 1
- 235000000385 Costus speciosus Nutrition 0.000 abstract 1
- 206010013789 Dry throat Diseases 0.000 abstract 1
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract 1
- 235000009815 Momordica Nutrition 0.000 abstract 1
- 241000218984 Momordica Species 0.000 abstract 1
- 235000002226 Ranunculus ficaria Nutrition 0.000 abstract 1
- 241000293861 Scrophularia nodosa Species 0.000 abstract 1
- 241001534869 Terminalia Species 0.000 abstract 1
- 241000606265 Valeriana jatamansi Species 0.000 abstract 1
- 235000014687 Zingiber zerumbet Nutrition 0.000 abstract 1
- 208000038016 acute inflammation Diseases 0.000 abstract 1
- 230000006022 acute inflammation Effects 0.000 abstract 1
- 230000006020 chronic inflammation Effects 0.000 abstract 1
- 230000036737 immune function Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 208000026435 phlegm Diseases 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 12
- 230000001629 suppression Effects 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 206010068319 Oropharyngeal pain Diseases 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 6
- 230000036760 body temperature Effects 0.000 description 6
- 239000003172 expectorant agent Substances 0.000 description 6
- 230000003419 expectorant effect Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 206010018691 Granuloma Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000012109 statistical procedure Methods 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 206010024796 Logorrhoea Diseases 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 235000010418 carrageenan Nutrition 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 206010006784 Burning sensation Diseases 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 3
- 240000001307 Myosotis scorpioides Species 0.000 description 3
- 206010067482 No adverse event Diseases 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 239000000679 carrageenan Substances 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 208000013403 hyperactivity Diseases 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- 208000030090 Acute Disease Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 244000132059 Carica parviflora Species 0.000 description 2
- 235000014653 Carica parviflora Nutrition 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 241000192041 Micrococcus Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 229940046011 buccal tablet Drugs 0.000 description 2
- 239000006189 buccal tablet Substances 0.000 description 2
- 230000004856 capillary permeability Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- 201000002882 Agraphia Diseases 0.000 description 1
- 206010002953 Aphonia Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000208365 Celastraceae Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 1
- 235000000336 Solanum dulcamara Nutrition 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- -1 dry below 60 °C Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000009438 liyan Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a Chinese medical preparation, particularly to medicine for treating throat diseases, which is made from raw materials, such as grosvenor momordica fruit, honeysuckle flower, medicine terminalia fruit, figwort root, manchurian wildginger, etc., according to specified component quantities. The medicine for treating throat diseases has the characteristics of simple prescription, low cost, reliable medicine effect and significant treating effect and has the effects of enriching yin, moistening the lung, reducing pathogenic fire, removing toxicity, removing stasis, eliminating diseases, clearing the throat, relieving the throat and alleviating pain. According to a pharmacodynamics experiment, the medicine of the present invention has the significant effects of resisting inflammation and alleviating pain and has the significant effect on acute and chronic inflammation. According to an in-vitro bacteria inhibiting experiment, the medicine of the present invention also has the significant effect of inhibiting the growth of bacteria and has a certain effect of strengthening the immunological function of a machine body. According to clinical experiments, the present invention has no toxic side effect, and the clinical total effective rate of the present invention is 97.5%. The present invention is suitable for signs, such as sore pharynx, dry throat, dry cough, little phlegm, etc., appearing in chronic pharyngitis.
Description
Technical field
The present invention relates to a kind of Chinese medicine preparation, promptly a kind of medicine for the treatment of laryngopharyngeal diseases.
Background technology
In prior art, chronic pharyngitis is commonly encountered diseases, a frequently-occurring disease clinically, and middle age sees more, particularly with the voice worker and be subjected to chemical gas, dust etc. for a long time the exciter is easier to suffer from, and have that the course of disease is long, patient's condition is touching, characteristics such as being easy to recover not repeatedly, very big to people's health effect.According to statistics, among the town dweller, its sickness rate accounts for the 10%-20% of specialty of pharyngolaryngology disease, is one of main diseases kind of medically studying at present, if untimely treatment rightly not only jeopardizes health, also influences operate as normal simultaneously, and patient itself is also very painful.The medicament categories of treatment laryngopharyngeal diseases is various, and effect differs, and its prescription is each has something to recommend him, but the prescription flavour of a drug are many, toxicity is big.Make an overstatement on the curative effect, promptly differ in fact, as " Herba Pileae Scriptae Tabellae " of strong sales on the market, produced by Jiangzhong Pharmaceutical Co., Ltd., Jiangxi Prov., drug effect effects such as its anti-inflammatory and antalgic are relatively poor, and curative effect is undesirable.
Summary of the invention
The present invention seeks to provides a kind of prescription science, curative effect to treat the medicine of laryngopharyngeal diseases more significantly at above-mentioned deficiency.
Technical solution of the present invention is: a kind of medicine for the treatment of laryngopharyngeal diseases is characterized in that it makes medicament by the raw material of following weight: Fructus Momordicae 200-300 gram, Flos Lonicerae 160-240 gram, Fructus Chebulae 120-180 gram, Radix Scrophulariae 120-180 gram, Herba Asari 24-36 gram.Be mixed and made into tablet, capsule, powder, pill, oral liquid or other conventional formulation by pharmaceutical carrier commonly used in above-mentioned each medicinal raw material and the pharmacy and additive or adjuvant.
Chronic pharyngitis is the chronic inflammatory disease of pharyngeal mucosa, is equivalent to " chronic throat obstruction, chronic pharyngitis " of the traditional Chinese medical science, and the cause of disease can be by repeatedly diseases caused by exogenous pathogenic factor sore throat and caused, many on the pathology asthenic fire is followed through last inflammation with YIN-deficiency of the lung and kidney, and it is main fumigating in throat, YIN-deficiency of the lung and kidney is basis of disease, and hyperactivity of deficient fire is the mark of disease.It is dried painful, scorching hot that the sore throat of hyperactivity of deficient fire often shows as throat, and sx after the polylogia is choked and coughed no expectorant, or a small amount of sticking expectorant is arranged, and asks diseases such as drink again and again.The treatment motherland medical science of this disease is thought when start with wholistic therapy from whole body.First among the we is monarch drug with sweet in the mouth nontoxic Fructus Momordicae cool in nature, clearing away lung-heat and moistening for dryness, clear and rich throat.The south Fructus Momordicae of commonly using among the people is taken after being infused in hot water or decoction for the clear and rich throat of tea-drinking, plays a major role in the side; Minister is sweet cold with full Flos Lonicerae, heat-clearing and toxic substances removing, the pharyngeal bacterial bearing rate of energy reduction crowd, principal drug assistance giving consideration to both the incidental and fundamental, the merit of enhancing clearing pharyngeal heat and detoxicating; Assistant is puckery and flat with Fructus Chebulae's picric acid, the therapeutic method to keep the adverse QI flowing downwards of astringing the lung sore-throat relieving, gram chronic cough." Bencao Tujing " cloud is controlled the phlegmatic cough discomfort in the throat, contains three several pieces.Fructus Chebulae's soup of " precious mirror of hygiene " has the effect of removing heat from the lung and relieving sorethroat sound producing, specially controls the aphonia agraphia, the meaning that as seen has assistant to help: the bitter sweet salty cold of Radix Scrophulariae, and nourishing YIN to lower pathogenic fire, the relieving restlessness detoxifcation is the key medicine of nourishing YIN to lower pathogenic fire, is mainly used to treat laryngopharynx swelling and pain.Liyan jiedu falls asthenic fire clearly, in two adjuvant drug principal drug assistance nourishing YIN and moistening the lung; Make with the hot temperature of Herba Asari, be assigned on a small quantity all refrigerant in case the cold and cool heresy of holding back, and have blunt good analgesic effect; It is hot cool nontoxic also can to add an amount of Oleum menthae, and clear light fragrance is kept away dirty detoxifcation, clearing throat.The all medicines of we share, and clear and rich not dry, giving consideration to both the incidental and fundamental is played nourishing YIN and moistening the lung altogether, the pathogenic fire reducing detoxifcation, and the merit of clearing throat is tried out clinically repeatly in chronic pharyngolaryngitis, truly has good effect.
This medicine method for making: with the tablet is example, above flavour of a drug, and Herba Asari extracts volatile oil, and volatile oil device is in addition collected, and is standby; Medicinal liquid after distillation device is in addition stored.Medicinal residues and Fructus Momordicae, four flavors such as Flos Lonicerae add water 10,8,6 times of amounts decoct each 2 three times, 1.5,1.5 hour, medicinal liquid after collecting decoction and the distillation filters, and filtrate is concentrated into relative density 1.20 (25 ℃), add ethanol and make that to contain alcohol amount be 70%, stir evenly, placed 24 hours, filter, filtrate recycling ethanol is not to there being the alcohol flavor, and being concentrated into relative density is the thick paste of 1.30 (60 ℃), add amount of starch, drying under reduced pressure below 80 ℃ is pulverized, cross 80 mesh sieves, add cane sugar powder 250g mixing, with 85% ethanol system granule, dry below 60 ℃, granulate, spray is with Oleum menthae, Herba Asari volatile oil, mixing is after airtight placement a few hours, make tablet, promptly.
Function with cure mainly: the detoxifcation of nourishing YIN and moistening the lung, pathogenic fire reducing; Eliminating stagnation dispel disease, clearing throat, relieving sore throat and pain.Be applicable to diseases such as pharyngalgia that chronic pharyngitis (hypopyretic laryngalgia) occurred, dry pharynx, dry cough, few expectorant.
Usage and dosage: buccal, one time 2,4 times on the one.(trade name: the Fructus Momordicae YANHOU PIAN)
Advantage of the present invention is: 1, show through pharmacodynamic experiment, medicine of the present invention has tangible antiinflammatory, analgesic activity, effect to acute and chronic inflammatory disease is all more obvious, and external bacteriostatic experiment also is the effect of obvious suppression bacterial growth, and has the effect of certain enhancing human body immunity function.2, show through clinical one of them test, by 41 routine chronic pharyngitis patients clinicals are observed, show that medicine of the present invention does symptoms such as painful, burning sensation, polylogia postemphasis and improve significantly for throat that chronic pharyngitis occurred, signs such as pharyngeal congestion and pharyngeal mucous membrane drying are improved significantly, blood leukocytes and body temperature have reduction trend slightly to the end, hepatic and renal function and blood pressure, heart rate are had no adverse effects, also there are not other side effect, its effect obviously is better than existing like product, and clinical total effective rate is 97.5%.3, with simple prescription, reasonably compatibility has been obtained favorable effects equally, and real is potion good medicine, and this medicine also has characteristics with low cost, that drug effect is reliable, evident in efficacy.
The specific embodiment
Further set forth beneficial effect of the present invention below in conjunction with test example, embodiment.
The Pharmacodynamic test of active extract of [test example 1] Drug therapy chronic pharyngolaryngitis of the present invention
Experimental unit
The Jilin Prov. Inst. of Chinese Medicine and Chinese Medical Science
Experiment material
Experimental drug: the Fructus Momordicae YANHOU PIAN, lot number 930514 is smeared administration in the oral cavity; The matched group feedwater, Herba Pileae Scriptae Tabellae is produced by pharmaceutical factory in the river, lot number 9308301.
Laboratory animal: healthy Kunming kind white mice, 18-22, male and female dual-purpose.Healthy Wistar kind vindication Mus 150-200g, based on male, provide by the court animal housing and animal housing of medicine inspecting institute, the animal quality certification number is: 930000005, ordinary nutrient agar is east, a Tianjin material factory product, first type and group B streptococcus, micrococcus catarrhalis, golden yellow and Staphylococcus albus bacterial strain provide by Norman Bethune Medical University's microorganism teaching and research room.
Method and result
One, antiinflammatory action
1, to the outgrowth influence of mice granuloma induced by implantation of cotton pellets
The white mice postoperative divides 5 groups at random, and 10 every group, one group is the normal control group, two groups is Herba Pileae Scriptae Tabellae 3g/kg group, and three, four, five groups are respectively Fructus Momordicae YANHOU PIAN 8g, 4g and 2g/kg group, and performing the operation began to smear in the oral cavity administration same day, once-a-day, continuous 7 days, 1h after the last administration, put to death animal, peel off and take out the granuloma induced by implantation of cotton pellets tissue, in 60 ℃ of baking oven inner dryings, weigh behind the 3h, deduct the raw cotton ball weight, be the granuloma net weight, the results are shown in Table 1:
The influence that table 1 Fructus Momordicae YANHOU PIAN forms the mice granuloma induced by implantation of cotton pellets
| Group | Dosage | The granuloma dry weight (X ± SD) | (mg) suppression ratio % |
| Matched group Herba Pileae Scriptae Tabellae Fructus Momordicae YANHOU PIAN Fructus Momordicae YANHOU PIAN Fructus Momordicae YANHOU PIAN | 3g/kg 8g/kg 4g/kg 2g/kg | 38.0±15.03 21.75±3.77 * 23.11±9.85 * 28.4±10.86 26.0±6.73 * | 42.7％ 39.18％ 25.26％ 31.57％ |
By table 1 as seen, Fructus Momordicae YANHOU PIAN 8g and 2g/kg dosage group and positive drug Herba Pileae Scriptae house sheet group all has obvious suppression effect (P＜0.05)
2. xylol brings out the influence of mouse ear edema
With 50 of body weight 18-22g mices, be divided into 6 groups at random, one group is matched group, and two groups are Herba Pileae Scriptae Tabellae 3g/kg group, three, four, five groups are respectively Fructus Momordicae YANHOU PIAN 8g, 4g and 2g/kg group, continuously administration was smeared seven days in the oral cavity, and after the last administration 30 minutes, with 100% dimethylbenzene 0.02m1, be applied to two sides, ear front and back, an animal left side, put to death animal after 15 minutes and lay the same position of left and right sides ear circle auricle with the 9mm card punch, torsion balance is weighed, and the results are shown in Table 2:
The influence of the mouse ear edema that table 2 Fructus Momordicae YANHOU PIAN xylol brings out
Group dosage dropsy of ear weight (mg) suppression ratio %
Matched group 18.3 ± 5.14
Herba Pileae Scriptae Tabellae 3g/kg 9.3 ± 4.35
* *49.2%
Fructus Momordicae YANHOU PIAN 8g/kg 8.2 ± 5.90
* *55.2%
Fructus Momordicae YANHOU PIAN 4g/kg 9.0 ± 4.46
* *50.8%
Fructus Momordicae YANHOU PIAN 2g/kg 13.2 ± 6.32 27.9%
Compare with matched group
* *P＜0.001
Experimental result shows that the mouse ear edema that Fructus Momordicae YANHOU PIAN xylol brings out has very obvious suppression effect (P＜0.00 1), and the suppression ratio of 8g/kg group can reach 55.2%.
3, on Carrageenan causes the influence of rat paw edema
Extracting male Wistar rat, body weight 150-180g, be divided into 5 groups at random, sweep intracavity continuously and smear administration, dosage and medication see Table 3, and after the last administration 1 hour, the carrageenin normal saline solution 0.1ml of the subcutaneous injection 1% of the right back sufficient sole of the foot of a Mus, survey the different time swelling degree of the paw, the t quiz statistics sees Table 3 between group:
Table 3 Fructus Momordicae YANHOU PIAN is to the influence of foot swelling due to the rat carrageenan
Group dosage number of animals causes swelling degree (X ± SD) (mm) of scorching back different time
G/kg * sky 1h 2h 3h 4h 5h 6h
Matched group 8 6.6 ± 1.55 12.9 ± 3.03 17.7 ± 3.51 19.9 ± 2.51 19.1 ± 2.24 17.7 ± 1.87
Herba Pileae Scriptae Tabellae 3 * 78 4.9 ± 1.05 9.94 ± 2.64 12.4 ± 2.57 15.7 ± 2.03
*15.1 ± 2.09
*13.8 ± 2.19
*
Fructus Momordicae YANHOU PIAN 8 * 78 4.4 ± 1.29
*10.7 ± 2.66 14.1 ± 1.97
*15.4 ± 1.59
* *15.7 ± 1.91
*14.6 ± 2.46
*
Fructus Momordicae YANHOU PIAN 4 * 78 4.2 ± 1.31
*11.2+2.67 16.4 ± 2.95 15.8 ± 1.69
*16.4 ± 1.88
*15.2 ± 1.6
*
Fructus Momordicae YANHOU PIAN 2 * 78 4.8 ± 1.58
*11.9+2.75 16.1 ± 1.96 16.8 ± 1.67
*16.4 ± 2.31
*15.5 ± 1.69
*
Compare with matched group
*P＜0.05,
*P＜0.01,
* *P＜0.001
The foot swelling that causes of three dosage groups of Fructus Momordicae YANHOU PIAN on Carrageenan as a result all has the obvious suppression effect, and strengthens its inhibitory action with dosage and strengthen.
4, to the influence of abdominal cavity capillary permeability
Get body weight 20-23g male mice in kunming, random packet, medication is the same, the blue 5ml/kg of tail vein injection 0.5% ivens 1 hour time the after the last administration, the 5min pneumoretroperitoneum is injected 0.7% acetic acid 10ml/kg, behind the 30min mice is put to death at interval, repeatedly wash the abdominal cavity, collect flushing liquor and be diluted to whole volume 5ml with distilled water; After adding 0.1mol/LNaOH 0.1ml, place 1h, get supernatant with 7230 spectrophotometer 610nm place colorimetrics, the result respectively organizes the OD value and is respectively: and matched group 0.39 ± 0.12 (X ± SD), Herba Pileae Scriptae Tabellae 0.41 ± 0.14; Fructus Momordicae YANHOU PIAN 8g/kg group, 0.37 ± 0.14; The 4g/kg group is 0.39 ± 0.13; 2g/kg group is 0.42 ± 0.16, relatively capillary permeability is had the trend of inhibition with matched group.
Two, the analgesic activity of Fructus Momordicae YANHOU PIAN
50 of healthy Kunming section mices that 18-22g is heavy, be divided into 5 groups at random, dosage and administration time, medication is the same, 40min after the last administration, every Mus lumbar injection 0.75% glacial acetic acid 0.1ml/10g body weight, injection back 5min begins to observe, the record mice is turned round the body number of times in 10min, adopt t method of inspection comparable group differences, the results are shown in Table 4:
Table 4 Fructus Momordicae YANHOU PIAN is to the analgesic activity of mice
Group dosage number of animals is turned round body number of times (X ± SD time) suppression ratio %
G/kg * sky only
Matched group 10 23 ± 7.03
Herba Pileae Scriptae Tabellae 3 * 7 10 11.9 ± 6.47
*48.3%
Fructus Momordicae YANHOU PIAN 8 * 7 10 11.3 ± 8.57
*51%
Fructus Momordicae YANHOU PIAN 4 * 7 10 14.6 ± 7.36
*36.2%
Fructus Momordicae YANHOU PIAN 2 * 7 10 13.3 ± 8.83
*42.7%
Compare with matched group
*P＜0.05,
*P＜0.01
Experimental result proves that the pain that the Fructus Momordicae YANHOU PIAN causes the lumbar injection glacial acetic acid has the obvious suppression effect, makes the body number of times of turning round that causes because of pain reduce (P＜0.01 and 0.05), and the high dose suppression ratio is 51%, shows that its analgesic activity is obvious.
Three, the Fructus Momordicae YANHOU PIAN is to the influence of function of immune system
1, to mouse immune organ weight's influence
Select the 18-20g healthy mice, be divided into 5 groups at random, dosage and medication and natural law see Table 5, and 1h after the last administration puts to death animal, cut open to get thymus and the spleen torsion balance is weighed, and press the 10g body weight and convert thymus and Pi index, the results are shown in Table 5:
Table 5 Fructus Momordicae YANHOU PIAN is to mouse immune organ significant effects (X ± SD)
Group dosage number of animals spleen index thymus index
G/kg * sky (mg/10g) (mg/10g)
Matched group 10 85.0 ± 25.0 33.9 ± 6.63
Herba Pileae Scriptae Tabellae 3 * 7 10 57.0 ± 7.7 43.2 ± 6.23
*
Fructus Momordicae YANHOU PIAN 8 * 7 10 64.0 ± 23 41.6 ± 11.7
Fructus Momordicae YANHOU PIAN 4 * 7 10 71.0 ± 19.0 41.7 ± 12.3
Fructus Momordicae YANHOU PIAN 2 * 7 10 72 ± 15.0 46.9 ± 8.92
*
Compare with matched group
*P＜0.01
Experiment shows, Fructus Momordicae YANHOU PIAN 2g/kg group can obviously increase thymus index, surplus two groups be increase trend, spleen index is not had obvious influence.
2, to the influence of mice carbon Cl
Select 50 of the healthy mices of body weight 18-22, be divided into 5 groups at random, administration was smeared 7 days in the oral cavity continuously, 30mln after the last administration, and tail vein injection india ink 0.05ml/10g body weight in injection back 2min and 15min socket of the eye venous blood collection 20 μ l, is dissolved in 2ml 0.1% * Na
2CO
3In the solution, put colorimetric under the 121 type spectrophotometer 650nm, measure OD value, and cut open get liver, spleen is weighed, and calculates carbon and cleans up index K and correction index α, t detection statistics comparison between group the results are shown in Table 6:
Table 6 Fructus Momordicae YANHOU PIAN is to the influence of the clear rate in mice carbon corridor (X ± SD)
Group dosage number of animals is cleaned up index k correction index α
G/kg * sky (10
-8* k)
Matched group 10 28.4 ± 9.0 4.13 ± 0.85
Herba Pileae Scriptae Tabellae 3 * 7 10 28.0 ± 6.0 4.39 ± 0.30
Fructus Momordicae YANHOU PIAN 8 * 7 10 26.0 ± 8.0 4.12 ± 0.67
Fructus Momordicae YANHOU PIAN 4 * 7 10 34.0 ± 7.0 4.37 ± 0.69
Fructus Momordicae YANHOU PIAN 2 * 7 10 41.0 ± 21.0 4.44 ± 0.85
As shown in Table 6, Fructus Momordicae YANHOU PIAN 4g and 2g/kg group all present certain increase trend to clear index K in mice carbon corridor and the correction clear index α in corridor, illustrate that this buccal tablet has certain promotion increase effect to function of immune system.
Four, the external bacteriostasis of Fructus Momordicae YANHOU PIAN
Add in the aseptic flat board after Fructus Momordicae YANHOU PIAN and Herba Pileae Scriptae Tabellae be diluted to variable concentrations with normal saline respectively, quantitatively add different types of culture medium mixing then, stand-by, and establish an aseptic culture medium and compare.After used bacterium pearl passed for 2 generations, make 3 * 10
8Ml/ (300,000,000/ml) bacterium liquid, inhale 5 μ l and drip on plating medium, smears back 37 ℃ with inoculating loop and cultivated observed result 24 hours by every kind of bacterium liquid.
Table 7 Fructus Momordicae YANHOU PIAN body outer suppressioning test result
Strain
Group alpha streptococcus group B streptococcus micrococcus catarrhalis staphylococcus aureus Staphylococcus albus
Matched group ++ ++ ++ ++ ++ ++ ++ ++ ++ ++
Sieve 200mg/ml-----
Chinese 100mg/ml-----
Fruit 50mg/ml+----
Sheet 25mg/ml+--++-
12.5mg/ml + ++ ++ +++ +++
Grass 200mg/ml---+-
Coral 100mg/ml++-+-
Coral 50mg/ml+++-++-
Sheet 25mg/ml ++ +++++-
12.5mg/ml ++ ++ ++ +++ -
"-" do not have bacterial growth fully, and "+" has several colony growths, and " ++ " has the single corner of skim lawn or comparatively dense, " +++" have thicker one deck lawn to grow, " ++ ++ " have very thick one deck lawn to grow.
The above results shows that Fructus Momordicae YANHOU PIAN external bacteriostasis under same concentrations obviously is better than Herba Pileae Scriptae Tabellae, to the minimal inhibitory concentration MIC of alpha streptococcus for being 12.5mg/ml.
Conclusion: Fructus Momordicae YANHOU PIAN pharmacological experiment shows, this buccal tablet has tangible antiinflammatory, analgesic activity, effect to acute and chronic inflammatory disease is all more obvious, external bacteriostatic experiment also is the effect of obvious suppression bacterial growth, and the effect with certain enhancing human body immunity function, for the treatment chronic pharyngitis provides theoretical basis preferably.
Report is looked in the clinical sight of [test example 2] Drug therapy chronic pharyngolaryngitis of the present invention
Clinical unit
Air force Changchun 461 hospitals
Clinical data
One, case is selected
This is organized among the 41 routine patients, male's 21 examples, women's 20 examples, age 19-30 year 11 examples, 31-40 year 10 examples, 41-50 year 10 examples, 51-60 year 7 examples, 61-65 year 3 examples.
Office rank: cadre 31 people, workman 8 people, student 1 people, housework 1 people.
Two, diagnostic criteria
Diagnostic criteria is pressed Ministry of Public Health and was formulated new Chinese medicine clinical research guideline in 1993, the clinical research guideline of new Chinese medicine treatment chronic pharyngitis is selected, all genus hyperactivity of deficient fire disease sore throat persons, card see throat do painful, scorching hot, polylogia after painful shape increase the weight of, choke and cough no expectorant, or glue expectorant on a small quantity, Dun Dun asks drink, pharyngeal congestion is kermesinus, mucosa drying, atrophy or have clinical manifestation persons such as lymph foilicie hyperplasia all can classify the object of observation as.
Observational technique
Allly meet diagnostic criteria person, fill in symptom, sign and auxiliary examination project by the observation plan requirement.Its symptom by do not have (-), light (+), in (++), heavy (+++) fill in, physico-chemical examination is filled in by domestic unified standard measurement unit.Observation gives the Fructus Momordicae YANHOU PIAN, one time 2,4 times on the one, suck clothes, two weeks were a course of treatment.Medicine has the big pharmaceutical Co. Ltd in Tonghua, Jilin Province side to provide, the clinical card of examining of new drug: (95) Ji is defended medicine clinical No. 7.Other relevant medicine of forbidding during the course of treatment, observation is carried out comprehensive review after finishing, and its The data self cross-reference carries out statistical procedures with the t check.
Observed result
One, criterion of therapeutical effect
Clinical research guideline by new Chinese medicine treatment chronic pharyngitis is divided clinical cure, produce effects, effective, invalid quadrupole.
Clinical cure: sx in the medication 10 days, two weeks disappears with interior clinical symptoms and sign.
Produce effects: two weeks of medication, most of sign disappeared with interior sx.
Effectively: two weeks of medication, the part sign disappeared with interior sx.The symptom integral value descends and occupy between 2/3～1/3.
Invalid: symptom has slightly to alleviate or do not have and alleviates after the medication, and sign does not have obvious improvement, treatment back integrated value decline less than 1/3.
Two, observed result
1, total effects
This is organized among the 41 routine patients, clinical cure 17 examples (41.5%), and produce effects 17 examples (41.5%), effective 6 examples (14.6%), total effective rate is 97.6%.Average 5.76 days onset days.
2, symptom curative effect
1 course of treatment of oral administration Fructus Momordicae YANHOU PIAN, throat is done symptom such as painful and is all had clear improvement, and adopts the rank test method to carry out statistical procedures, has significant difference before and after the treatment, the results are shown in Table 1.
Table 1 Fructus Momordicae YANHOU PIAN symptom curative effect table
| Symptom | n | Before the treatment | After the treatment | U | P |
| +++ ++ + - | +++ ++ + - | ||||
| Heavily choking behind the dried painful burning sensation polylogia of throat, it is thirsty to cough no expectorant | 41 41 41 41 41 | 26 13 1 1 7 22 11 1 15 12 10 4 2 12 12 15 1 11 18 11 | 0 1 17 23 0 4 9 28 0 0 3 38 0 0 3 38 0 0 1 40 | 7.65 6.57 5.86 6.39 | * * * * |
Annotate:
*P＜0.01
3, the curative effect that sign is improved
1 course of treatment of per os buccal Fructus Momordicae YANHOU PIAN improves significantly to signs such as pharyngeal congestion and pharyngeal mucous membrane dryings, adopts the rank test method to carry out statistical procedures, has significant difference before and after the treatment, sees Table 2.
Table 2 Fructus Momordicae YANHOU PIAN is to the influence of signs such as pharyngeal congestion
| Sign | n | Before the treatment | After the treatment | U | P |
| +++ ++ + - | +++ ++ + - | ||||
| The enlargement of the dry atrophy lymph foilicie hyperplasia of pharyngeal congestion mucosa cervical lymph node | 41 41 41 41 | 11 26 4 0 4 11 10 0 4 22 14 1 0 8 16 17 | 0 0 13 28 0 0 7 34 0 3 18 20 0 1 16 24 | 7.88 4.47 5.96 2.05 | * * * |
4, to the influence of tip blood leukocytes
1 course of treatment of oral administration Fructus Momordicae YANHOU PIAN, the tip blood leukocytes downward trend is arranged, through carrying out statistical procedures, have significant difference before and after the treatment with the t method of inspection, the results are shown in Table 3.
Table 3 Fructus Momordicae YANHOU PIAN is to WBC influence (X ± SD)
| Sign WBC | n 41 | Treat preceding 10.21 ± 2.09 | Treatment back 8.60 ± 0.89 | t 5.76 | p * |
Annotate:
*P＜0.01
5, to the influence of body temperature
Through taking this product after 1 course of treatment, be that the body temperature that raises has downward trend, through carrying out statistical procedures with the t method of inspection.There is significant difference before and after the treatment, the results are shown in Table 4.
Table 4 Fructus Momordicae YANHOU PIAN is to the influence of body temperature (X ± SD)
| Sign | n | Before the treatment | After the treatment | t | p |
| Body temperature | 41 | 36.39±0.49 | 36.15±0.25 | 6.54 | ＜0.01 |
6, to the influence of hepatic and renal function
Take this product after 1 course of treatment, liver function, routine urinalysis does not all have change, and blood pressure, heart rate are had no adverse effects, and other side effect do not occur.
Brief summary
Observe by 41 routine chronic pharyngitis patients clinicals, show that the Fructus Momordicae YANHOU PIAN does symptom such as painful, burning sensation and improve significantly for the throat due to the chronic pharyngitis (hypopyretic laryngalgia card), the trend that simultaneously tip blood leukocytes and body temperature is had reduction, hepatic and renal function and blood pressure, heart rate are had no adverse effects, other side effect do not occur.Clinical obvious effective rate is 83%.Total effective rate is 97.6%.Pharmacological tests shows that this product has effects such as antiinflammatory, analgesia, conforms to clinical efficacy, can assert that the Fructus Momordicae YANHOU PIAN is the ideal medicament that is used for chronic pharyngitis, can apply.
[embodiment 1] Fructus Momordicae YANHOU PIAN
The Fructus Momordicae YANHOU PIAN is made 1000 by Fructus Momordicae 250 grams, Flos Lonicerae 200 grams, Fructus Chebulae's 150 grams, Radix Scrophulariae 150 grams, Herba Asari 30 grams, an amount of Oleum menthae, cane sugar powder, starch by preceding method.
Claims (1)
1, a kind of medicine for the treatment of laryngopharyngeal diseases is characterized in that the medicament that it is made by the raw material of following weight: Fructus Momordicae 200-300 gram, Flos Lonicerae 160-240 gram, Fructus Chebulae 120-180 gram, Radix Scrophulariae 120-180 gram, Herba Asari 24-36 gram.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410010708 CN1220515C (en) | 2004-02-22 | 2004-02-22 | Medicine for treating throat disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410010708 CN1220515C (en) | 2004-02-22 | 2004-02-22 | Medicine for treating throat disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1559494A CN1559494A (en) | 2005-01-05 |
| CN1220515C true CN1220515C (en) | 2005-09-28 |
Family
ID=34440006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410010708 Expired - Fee Related CN1220515C (en) | 2004-02-22 | 2004-02-22 | Medicine for treating throat disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1220515C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101411782B (en) * | 2008-11-11 | 2011-06-08 | 南京同仁堂药业有限责任公司 | Pharmaceutical composition for treating acute pharyngitis and preparation method thereof |
| CN101856424B (en) * | 2009-09-03 | 2011-10-05 | 张钦 | Chinese medicament for treating chronic pharyngitis |
| CN115227624B (en) * | 2022-08-30 | 2023-11-14 | 北京臻味坊食品有限公司 | Infant skin care oil containing nut oil |
-
2004
- 2004-02-22 CN CN 200410010708 patent/CN1220515C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1559494A (en) | 2005-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1947754A (en) | Medicine for treating infantile asthma and its prepn. method | |
| CN1314387C (en) | Children cough and asthma treating Chinese traditional medicine and its preparation | |
| CN1733146A (en) | Bitter buccal tablet for clearing and moistening throat | |
| CN1225252C (en) | Process for preparing composition comprising medicinal herb extract for preventing and curing arthritis and composition thereof | |
| CN1608662A (en) | Medicine with antiphlogistic, analgetic, microbiostatic and diuretic effects | |
| CN1903254A (en) | Compound medicine for treating wind-heat type cold and preparing method thereof | |
| CN101053619A (en) | Medicine for treating pulmonary fibrosis | |
| CN1220515C (en) | Medicine for treating throat disease | |
| CN1056298C (en) | External use medicine for treating soft tissue injury and its producing method | |
| CN1197612C (en) | Chinese medicine preparation for treating lithiasis in urinary system and urethral infection, and preparing method thereof | |
| CN100335044C (en) | Rhinitis treating soft medicinal capsule and preparation process thereof | |
| CN100337658C (en) | Chinese medicine composition for treating cold anemopyretic syndrome, and its preparing method | |
| CN1679658A (en) | Chinese medicine preparation for treating AIDS and process thereof | |
| CN1840008A (en) | Chinese medicinal granule for clearing pharynx and moistening throat and preparation method thereof | |
| CN1251751C (en) | Chinese traditional medicine for treating chronic liver disease and anti hepatic fibrosis | |
| CN1903240A (en) | Medicinal use of Aralia continentalis kitag | |
| CN1308019C (en) | Chinese medicinal composition for treating chronic pelvic inflammation and preparation method thereof | |
| CN1239199C (en) | Medicine for treating gastritis and peptic ulcer | |
| CN1261156C (en) | Medicine for treating chronic gastroenteritis and colitis | |
| CN1314388C (en) | Four component tumeric tablet and its preparation method | |
| CN1593564A (en) | Medicine for treating cold and its preparing process | |
| CN1839950A (en) | Coryza-treating pharmaceutical compositions and its preparing process and uses | |
| CN1559535A (en) | Chinese medicine oral preparaton for treating urinary system infestation and its preparation method | |
| CN1289139C (en) | Medicine for treating colitis and its preparing method | |
| CN1519012A (en) | Soft capsule of dahurian rhododendron leaf and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20051220 Pledge (preservation): Preservation |
|
| PD01 | Discharge of preservation of patent |
Date of registration: 20060620 Pledge (preservation): Preservation |
|
| PP01 | Preservation of patent right |
Effective date of registration: 20061214 Pledge (preservation): Preservation |
|
| PD01 | Discharge of preservation of patent |
Date of cancellation: 20071214 Pledge (preservation): Preservation registration |
|
| ASS | Succession or assignment of patent right |
Owner name: TONGHUA ZHONGSHENG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: FANGDA PHARMACEUTICAL CO LTD, TONGHUA CITY Effective date: 20150721 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20150721 Address after: Jiang Road 130010 Tonghua city of Jilin Province Dongchang District No. 900 Patentee after: Tonghua Zhongsheng Pharmaceutical Co.,Ltd. Address before: Jiang Road 134000 Tonghua city of Jilin Province Dongchang District No. 50 Patentee before: Tonghua Fangda Pharmaceutical Co.,Ltd. |
|
| PP01 | Preservation of patent right | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20180601 Granted publication date: 20050928 |
|
| PD01 | Discharge of preservation of patent | ||
| PD01 | Discharge of preservation of patent |
Date of cancellation: 20240222 Granted publication date: 20050928 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050928 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |